Related Experiment Video
Updated: Aug 13, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Increased Myosin light chain 9 expression during Kawasaki disease vasculitis
Hironobu Kobayashi1,2,3, Motoko Y Kimura3,4, Ichita Hasegawa3
1Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Insights
Myosin light chain 9 (Myl9) is elevated in children with Kawasaki disease (KD), a serious vasculitis. Higher Myl9 levels correlate with inflammation and predict response to IVIG therapy, offering a potential biomarker for KD management.
Area of Science:
- Cardiovascular Research
- Immunology
- Pediatric Medicine
Background:
- Kawasaki disease (KD) is a critical pediatric vasculitis with unknown etiology.
- Immune response and platelet activation are implicated in KD pathogenesis.
- Myosin light chain 9 (Myl9), involved in cell contractility and released by platelets, has not been studied in relation to KD.
Purpose of the Study:
- To investigate the role and clinical significance of Myosin light chain 9 (Myl9) in Kawasaki disease (KD).
- To assess Myl9 as a potential biomarker for KD inflammation and treatment response.
Main Methods:
- Measured plasma Myl9 concentrations in KD patients and controls.
- Evaluated in vitro platelet Myl9 release in KD patients.
- Assessed Myl9 expression in mouse models of KD vasculitis and human autopsy tissues.
Main Results:
- Plasma Myl9 levels were significantly higher in acute KD patients versus controls.
- Myl9 levels decreased with IVIG therapy in responders but not non-responders.
- Elevated Myl9 expression was found in mouse and human cardiac tissues, preceding inflammation in mice.
Conclusions:
- Myosin light chain 9 (Myl9) expression is significantly increased in Kawasaki disease (KD) vasculitis.
- Plasma Myl9 may serve as a valuable biomarker for assessing KD inflammation and predicting IVIG responsiveness.
Introduction:
Kawasaki disease (KD) is an acute systemic vasculitis that predominantly afflicts children. KD development is known to be associated with an aberrant immune response and abnormal platelet activation, however its etiology is still largely unknown. Myosin light chain 9 (Myl9) is known to regulate cellular contractility of both non-muscle and smooth muscle cells, and can be released from platelets, whereas any relations of Myl9 expression to KD vasculitis have not been examined.
Methods:
Plasma Myl9 concentrations in KD patients and children with febrile illness were measured and associated with KD clinical course and prognosis. Myl9 release from platelets in KD patients was also evaluated in vitro. Myl9 expression was determined in coronary arteries from Lactobacillus casei cell wall extract (LCWE)-injected mice that develop experimental KD vasculitis, as well as in cardiac tissues obtained at autopsy from KD patients.
Results And Discussion:
Plasma Myl9 levels were significantly higher in KD patients during the acute phase compared with healthy controls or patients with other febrile illnesses, declined following IVIG therapy in IVIG-responders but not in non-responders. In vitro, platelets from KD patients released Myl9 independently of thrombin stimulation. In the LCWE-injected mice, Myl9 was detected in cardiac tissue at an early stage before inflammatory cell infiltration was observed. In tissues obtained at autopsy from KD patients, the highest Myl9 expression was observed in thrombi during the acute phase and in the intima and adventitia of coronary arteries during the chronic phase. Thus, our studies show that Myl9 expression is significantly increased during KD vasculitis and that Myl9 levels may be a useful biomarker to estimate inflammation and IVIG responsiveness to KD.
Related Concept Videos
Myocarditis I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

